KDM6A was recurrently altered in our cohort (8.1%) and associated with RUNX1::RUNX1T1-rearrangement, in contrast with previous publications in which KDM6A mutations were only described in 0.5% to 3% of pediatric patients with AML, and enrichment of KDM6A mutation has not been previously described in children with CBF-AML.16 This evidence concerns the gene KDM6A and acute myeloid leukemia.